About Dr. Sartor
I am a globally recognized expert in prostate cancer with more than 30 years of experience dedicated to advancing care for men, particularly those facing advanced, treatment-resistant disease. I currently lead the newly established Transformational Prostate Cancer Research Center at the East Jefferson Hospital Cancer Center, where I care for patients and continue my research. My current focus is on improving both the quantity and quality of life for men with prostate cancer.
I earned my MD with honors from Tulane University School of Medicine and completed my training at the University of Pennsylvania, Tulane, and the National Cancer Institute (NCI), where I began pioneering work on novel therapeutics for prostate cancer. Over the course of my career, I have held leadership roles at institutions including
LSU Health Sciences Center, Dana-Farber Cancer Institute/Harvard Medical School, Tulane University, and most recently, Mayo Clinic, where I served as Professor of Medical Oncology, Director of Radiopharmaceutical Trials, and Chief of the Genitourinary Cancer Disease Group.
I have authored over 500 peer-reviewed publications and played key roles in numerous international clinical trials that led to FDA-approved treatments for prostate cancer, including Quadramet (Sm-153 EDTMP), Jevtana (cabazitaxel), Xofigo (radium-223), and Pluvicto (PSMA-617 Lu-177).